The Heat Biolics COVID-19 vaccine caused the expansion of both “killer” CD8 + T cells that destroy virus-infected cells, as well as “helper” CD4 + T cells that help produce very specific antibodies. Both groups of T cells were shown to release cytokines that boost the anti-viral immune response and, after vaccination, CD8 + T memory cells migrated to the lungs and airways – the site specific for tissues of interest for SARS-CoV- infection. 2. These resident memories of lung tissue and airways CD8 + T are essential in assembling an effective response to respiratory viruses.
Natasa Strbo, MD, DSc, Assistant Professor of Microbiology and Immunology at the University of Miami Miller School of Medicine and co-developer of the Heat gp96 platform, commented, “We are very encouraged by the animal data generated around the COVID vaccine. 19 and look forward to publishing the full details of this study in the coming weeks. Separately, we have observed some important immune responses generated by the SARS-CoV-2 vaccine after a single injection, including SARS-CoV-2 specific CD8 + and CD4 + T cells in the lungs and airways “.
Jeff Wolf, CEO of Heat Biology, commented, “We are encouraged by the progress being made by other companies developing vaccines against COVID-19. However, unlike most of these approaches that primarily drive an antibody response, vaccines Our COVID-19 is designed to primarily target T cell immunity along with antibody responses and innate immunity. As a result, we believe our vaccine has the potential to be used as an independent vaccine, or in combination with these approaches. Extraordinary support of Dr. Strbo and her team at the University of Miami, as well as the team at Heat who worked around the clock in view of the pandemic urgency.We look forward to providing further updates as soon as possible. as soon as possible. “
Heat Biologics is a biopharmaceutical company focused on developing first-class therapies to modulate the immune system. The company gp96 platform was created to activate immune responses against cancer or pathogenic antigens. The company has numerous product development candidates using the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccination program in preclinical development. Furthermore, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is being recorded in a Phase 1 trial.
www.heatbio.com, and also follow us further tweet. “data-reagid =” 24 “> For more information, please visit: www.heatbio.com, and also follow us on Twitter.
The story goes on